Globant Ventures

Globant Ventures is the corporate venture arm of Globant, the publicly listed Latin American digital services and software engineering firm. The fund deploys $250k to $1M checks at seed and Series A, with explicit AI thematic positioning and a healthcare-relevant lens that includes AI/ML in healthcare and health-IT software. The CVC’s strategic logic is to identify disruptive AI and software companies that complement Globant’s enterprise services franchise.

The firm’s natural fit is with founders building enterprise software with credible AI moats, particularly where the technology has cross-border deployment potential and could become a partner or product in Globant’s broader ecosystem. For healthcare founders specifically, this means AI-enabled clinical workflow, healthcare-specific large language model applications, software for pharma and life sciences enterprises, and health-IT platforms with global enterprise distribution potential. Founders building DTC consumer health, biotech, or pure local-market software without enterprise distribution thesis are not the natural target.

Geographically, Globant’s footprint is genuinely global (Argentina, US, UK, India, and beyond), and the firm can plausibly help LatAm founders syndicate to international capital and recruit globally. For Argentine and broader Hispanic-LatAm founders, the firm is one of the few regional CVCs with international credibility. For pure US-headquartered founders, the strategic value is real but indirect.

The right entry path is via Globant’s enterprise services teams (where strategic synergy can be identified), an existing portfolio founder, or a regional VC who has co-invested. The firm reads partner-led decks and is responsive to clear AI-thematic pitches. The pitch should lead with the AI moat (data, model, customer outcomes), the enterprise distribution angle, and a credible plan for cross-border GTM.

Caveats. Strategic CVCs introduce co-sale, ROFR, and other rights that can complicate downstream rounds; engage experienced counsel. The firm’s healthcare-specific portfolio depth is not as visible publicly as its broader enterprise AI portfolio; reference calls with portfolio founders are essential. The check size is moderate; for founders raising larger seeds, Globant Ventures should be a participant alongside a real lead. For LatAm founders building enterprise AI with healthcare applications and credible global distribution thesis, Globant Ventures is a meaningful strategic partner; for purely consumer or local-market plays, the fit is weaker.